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ABSTRACT
Background
Alcohol, tobacco, and illegal drug use cause considerable morbidity and mortality, but good
cross-national epidemiological data are limited. This paper describes such data from the first 17
countries participating in the World Health Organization’s (WHO’s) World Mental Health (WMH)
Survey Initiative.
Methods and Findings
Household surveys with a combined sample size of 85,052 were carried out in the Americas
(Colombia, Mexico, United States), Europe (Belgium, France, Germany, Italy, Netherlands, Spain,
Ukraine), Middle East and Africa (Israel, Lebanon, Nigeria, South Africa), Asia (Japan, People’s
Republic of China), and Oceania (New Zealand). The WHO Composite International Diagnostic
Interview (CIDI) was used to assess the prevalence and correlates of a wide variety of mental
and substance disorders. This paper focuses on lifetime use and age of initiation of tobacco,
alcohol, cannabis, and cocaine. Alcohol had been used by most in the Americas, Europe, Japan,
and New Zealand, with smaller proportions in the Middle East, Africa, and China. Cannabis use
in the US and New Zealand (both 42%) was far higher than in any other country. The US was
also an outlier in cocaine use (16%). Males were more likely than females to have used drugs;
and a sex–cohort interaction was observed, whereby not only were younger cohorts more
likely to use all drugs, but the male–female gap was closing in more recent cohorts. The period
of risk for drug initiation also appears to be lengthening longer into adulthood among more
recent cohorts. Associations with sociodemographic variables were consistent across countries,
as were the curves of incidence of lifetime use.
Conclusions
Globally, drug use is not distributed evenly and is not simply related to drug policy, since
countries with stringent user-level illegal drug policies did not have lower levels of use than
countries with liberal ones. Sex differences were consistently documented, but are decreasing
in more recent cohorts, who also have higher levels of illegal drug use and extensions in the
period of risk for initiation.
The Editors’ Summary of this article follows the references.
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Alcohol, tobacco, and illegal drug use are held responsible
for considerable mortality and morbidity [1], but in the most
recent World Health Organization (WHO) Global Burden of
Disease estimates, the authors unanimously asserted that
better epidemiological data on use were needed, particularly
in less established market economies [2–4]. This paper
presents data on lifetime alcohol, tobacco, cannabis, and
cocaine use from rigorously conducted ﬁeld surveys using a
common research approach in the ﬁrst 17 countries to
participate in the WHO’s World Mental Health (WMH) Survey
Initiative [5,6]. A number of less established market econo-
mies are included in this set of countries.
Cross-national research on diseases and their putative risk
factors has long been acknowledged as extremely difﬁcult
[7,8]. The creation of an international classiﬁcation of causes
of death advanced this line of inquiry [9], and was followed by
the developments of international classiﬁcations and meas-
urement approaches for chronic conditions, including
mental disorders [10]. Historically, cross-national compar-
isons for alcohol and tobacco were undertaken using
correlation studies of nation-level consumption (e.g., taxation
data) plotted in relation to pertinent causes of death (e.g.,
liver cirrhosis, lung cancer). There is continuing uncertainty,
however, about the comparability of death certiﬁcation
practices across countries, and for illegal drugs particularly,
ofﬁcial statistics are considered unreliable in many countries
[11].
Following reﬁnements in survey research, well-speciﬁed
and standardised methods were developed for population
surveys on alcohol use [12–14], illegal drug use [15], and
tobacco use [16]. Cross-national elaboration of these proto-
cols is difﬁcult [14,17], though, and has consequently been
limited. More qualitative ‘‘rapid assessment’’ methods, widely
adopted in the emerging market economies and valuable for
within-country planning purposes, are difﬁcult to use for the
purposes of cross-national comparisons [18].
Cross-national comparisons within regions have been
conducted in Europe [19–22] and in Panama, Central
America, and the Dominican Republic (PACARDO) [23].
Efforts to collate existing survey data on alcohol and tobacco
use (and abstention) have been undertaken through the
WHO’s Global Status Report on Alcohol [24] and the Tobacco or
Health: Global Status Report [25]. Recently, the Global Youth
Tobacco Survey (GYTS) [26] and a cross-national survey
known as the Gender, Alcohol, and Culture: an International
Study (GENACIS) [20], included population surveys of
tobacco or alcohol use in selected populations in multiple
countries. None of these, though, examined alcohol, tobacco,
and illegal drug use concomitantly, in all regions, and across
all ages.
The current study presents data on basic epidemiological
patterns of alcohol, tobacco, cannabis, and cocaine use in 17
countries participating to date in the WMH surveys [5,6]. The
WMH countries include countries in which cannabis use has
been strongly prohibited (the US) as well as countries in
which a harm reduction policy has long been in place (the
Netherlands). The survey also includes cocaine source
(Colombia) and consumer (US, Europe) countries.
This paper has the following objectives: (a) document the
cumulative (lifetime) use of alcohol, tobacco, cannabis, and
cocaine in each country, with some focus on young adults; (b)
consider sociodemographic correlates of these types of drug
use; and (c) examine the age of onset (AOO) distribution of
such drug use.
Method
Participants
Eighteen surveys were carried out in 17 countries in the
Americas (Colombia, Mexico, US), Europe (Belgium, France,
Germany, Italy, Netherlands, Spain, Ukraine), the Middle East
and Africa (Israel, Lebanon, Nigeria, South Africa), Asia
(Japan, and separate surveys in Beijing and Shanghai in the
People’s Republic of China), and Oceania (New Zealand). This
set of countries was determined by availability of collabo-
rators in the country who were able to obtain funding for the
survey and complete the World Mental Health Surveys
(WMHS) protocol. Details of each sample are presented in
Table 1 (see also http://www.hcp.med.harvard.edu/wmh/) [27].
All surveys were based on multistage probability samples.
All interviews were carried out face-to-face by trained lay
interviewers. The six Western European surveys were carried
out jointly [28,29]. Consistent use of a standardized interview
translation protocol, training procedures, and ﬁeld quality
control monitoring were used to minimize between-country
variation in data quality [30].
Sample sizes ranged from 2,372 (Netherlands) to 12,992
(New Zealand), with a total of 85,052 participating adults.
Response rates range from a high value of 88% (Colombia) to
a low value of 46% (France), with a weighted average response
rate of 70%. As described in detail elsewhere [27], internal
subsampling was used to reduce respondent burden by
dividing the interview into two parts. All participants
completed Part I, which included core standardised items to
assess conditions of central interest, including whether the
participant was a current or former tobacco smoker. Part II
included standardised items about correlates and disorders of
secondary interest. Part II was administered to an enriched
subsample (n ¼ 43,249) that included 100% of those who met
criteria for any Part I disorder and a random subsample of
approximately 25% of other Part I respondents. As alcohol
and illicit drug use were assessed in Part II, the Part II sample
is considered in this report. Part II cases were weighted by the
inverse of their probability of selection in order to adjust for
differential sampling. There was also poststratiﬁcation adjust-
ment to bring the sample distributions into balance with
population sociodemographic and geographic distributions
[6]. The complexity of these adjustments differed across
countries depending on the amount of population data
available for poststratiﬁcation. More details about sampling
and weighting procedures are discussed elsewhere [27].
Measures
All WMH surveys used the WHO Composite International
Diagnostic Interview, Version 3.0 (Composite International
Diagnostic Interview [CIDI] 3.0), a fully structured diagnostic
interview for psychiatric conditions [5,6]. Within this assess-
ment, participants were asked if they had ever used (a)
alcohol, (b) tobacco (cigarettes, cigars, or pipes), (c) cannabis
(marijuana, hashish), and (d) cocaine. Those who had used
these drugs were asked about the AOO of use of each drug
class, except in New Zealand, Japan, France, Germany,
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Drug Use across the GlobeTable 1. Characteristics of Studies Included in the World Mental Health Survey
Country Survey Sample Characteristics
a Dates Age Sample Size Response
Rate
b
Part I Part II Part II and
Age  44
4c
Belgium ESEMeD Stratified multistage clustered probability sample of
individuals residing in households from the national
register of Belgium residents. NR
2001–2002 18þ 2,419 1,043 486 50.6
Colombia NSMH Stratified multistage clustered area probability sample
of household residents in all urban areas of the country
(approximately 73% of the total national population)
2003 18–65 4,426 2,381 1,731 87.7
France ESEMeD Stratified multistage clustered sample of working
telephone numbers merged with a reverse directory (for
listed numbers). Initial recruitment was by telephone,
with supplemental in-person recruitment in households
with listed numbers. NR
2001–2002 18þ 2,894 1,436 727 45.9
Germany ESEMeD Stratified multistage clustered probability sample of
individuals from community resident registries. NR
2002–2003 18þ 3,555 1,323 621 57.8
Italy ESEMeD Stratified multistage clustered probability sample of
individuals from municipality resident registries. NR
2001–2002 18þ 4,712 1,779 853 71.3
Israel NHS Stratified multistage clustered area probability sample of
household residents. NR
2002–2004 21þ 4,859 4,859 2,502 72.6
Japan WMHJ2002–
2003
Unclustered two-stage probability sample of individuals
residing in households in four metropolitan areas (Fukiage,
Kushikino, Nagasaki, Okayama)
2002–2003 20þ 2,436 887 282 56.4
Lebanon LEBANON Stratified multistage clustered area probability sample of
household residents. NR
2002–2003 18þ 2,857 1,031 595 70.0
Mexico M-NCS Stratified multistage clustered area probability sample of
household residents in all urban areas of the country
(approximately 75% of the total national population).
2001–2002 18–65 5,782 2,362 1,736 76.6
Netherlands ESEMeD Stratified multistage clustered probability sample of
individuals residing in households that are listed in
municipal postal registries. NR
2002–2003 18þ 2,372 1,094 516 56.4
New Zealand NZMHS Stratified multistage clustered area probability sample of
household residents. NR
2004–2005 16þ 12,992 7,435 4,242 73.3
Nigeria NSMHW Stratified multistage clustered area probability sample of
households in 21 of the 36 states in the country,
representing 57% of the national population. The surveys
were conducted in Yoruba, Igbo, Hausa, and Efik languages.
2002–2003 18þ 6,752 2,143 1,203 79.3
People’s
Republic
of China
B-WMH,
S-WMH
Stratified multistage clustered area probability sample of
household residents in the Beijing and Shanghai
metropolitan areas.
2002–2003 18þ 5,201 1,628 570 74.7
South Africa SASH Stratified multistage clustered area probability sample of
household residents. NR
2003–2004 18þ 4,315 4,315 3,130 87.1
Spain ESEMeD Stratified multistage clustered area probability sample of
household residents. NR
2001–2002 18þ 5,473 2,121 960 78.6
Ukraine CMDPSD Stratified multistage clustered area probability sample of
household residents. NR
2002 18þ 4,725 1,720 541 78.3
US NCS-R Stratified multistage clustered area probability sample of
household residents. NR
2002–2003 18þ 9,282 5,692 3,197 70.9
aMost WMH surveys are based on stratified multistage clustered-area probability household samples in which samples of areas equivalent to counties or municipalities in the US were
selected in the first stage followed by one or more subsequent stages of geographic sampling (e.g., towns within counties, blocks within towns, households within blocks) to arrive at a
sample of households, in each of which a listing of household members was created and one or two people were selected from this listing to be interviewed. No substitution was allowed
when the originally sampled household resident could not be interviewed. These household samples were selected from census area data in all countries other than France (where
telephone directories were used to select households) and the Netherlands (where postal registries were used to select households). Several WMH surveys (Belgium, Germany, Italy) used
municipal resident registries to select respondents without listing households. The Japanese sample is the only totally unclustered sample, with households randomly selected in each of
the four sample areas and one random respondent selected in each sample household. Nine of the 15 surveys are based on nationally representative (NR) household samples, while two
others are based on nationally representative household samples in urbanized areas (Colombia, Mexico).
bThe response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the
denominator households known not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of
the survey.
cAll countries, with the exception of Nigeria, People’s Republic of China, and Ukraine (which were age restricted to  39) were age restricted to  44.
B-WMH, The Beijing World Mental Health Survey; CMDPSD, Comorbid Mental Disorders during Periods of Social Disruption; ESEMeD, The European Study of the Epidemiology of Mental
Disorders; LEBANON, Lebanese Evaluation of the Burden of Ailments and Needs of the Nation; M-NCS, The Mexico National Comorbidity Survey; NCS-R, The US National Comorbidity
Survey Replication; NHS, Israel National Health Survey; NR, nationally representative; NSMH, The Colombian National Study of Mental Health; NSMHW, The Nigerian Survey of Mental
Health and Wellbeing; NZMHS, New Zealand Mental Health Survey; SASH, South Africa Health Survey; S-WMH, The Shanghai World Mental Health Survey; WMHJ2002–2003, World Mental
Health Japan Survey.
doi:10.1371/journal.pmed.0050141.t001
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Drug Use across the GlobeBelgium, the Netherlands, Italy, and Spain, where age of ﬁrst
tobacco smoking was not assessed.
Sex and age of all participants was recorded. The following
covariates deﬁned as at year of interview were also studied: (a)
completed years of education (grouped as: no education,
some primary, primary ﬁnished, some secondary, secondary
ﬁnished, some college, and college or more); (b) relationship
status (never married, previously married, married-cohab-
itating); (c) employment (homemaker, retired, other [includ-
ing unemployed], working/student); and (d) family income
(low, low-average, high-average, and high, deﬁned via assess-
ment of total household income, with in-country medians
calculated). In the case of household income, the standard
international labour economics method [31] was used to
deﬁne low-income respondents as those whose after-tax
household income per family member was less than half the
median within their country. Low-average income was
deﬁned as up to the median income per family member in
the country. High-average income was deﬁned as income per
family member above the median up to three times the
median, while high income was deﬁned as income per family
member above three times the population median.
Retrospective AOO reports were based on a question series
designed to avoid the implausible response patterns obtained
in using the standard Composite International Diagnostic
Interview [CIDI] AOO question [32]. Experimental research
shows this question sequence yields responses with much
more plausible AOO distributions than the standard Com-
posite International Diagnostic Interview [CIDI] AOO ques-
tion [33]. Although AOO questions were asked both about
important symptoms (e.g., ﬁrst panic attack) and full
syndromes, the ages used here are for ﬁrst use of each drug.
Training and Field Procedures
The central WMH staff trained bilingual supervisors in
each country. Consistent interviewer training documents and
procedures were used across surveys. The WHO translation
protocol was used to translate instruments and training
materials. Standardized descriptions of the goals and proce-
dures of the study, data uses and protection, and participants’
rights were provided in written and verbal form to all
respondents before verbal informed consent was secured.
Quality control protocols were standardized across countries
to check on interviewer accuracy and to specify data cleaning
and coding procedures. The institutional review board of the
organisation that coordinated the survey in each country
approved and monitored compliance with procedures for
obtaining informed consent and protecting participants. A
more detailed discussion of these procedures is presented
elsewhere [27,30].
Data Analysis
The cumulative incidence of use was estimated in the
conventional fashion, as the proportion of respondents who
ever had a given disorder up to their age at interview. AOO
distributions and projected lifetime risk at given ages were
estimated using the two-part actuarial method implemented
in SAS 8.2 [34]. The actuarial method differs from the more
familiar Kaplan-Meier [35] method in using a more accurate
way of estimating the timing of onsets within a given year
[36], although both methods assume constant conditional risk
of onset at a given year of life across cohorts. Sociodemo-
graphic predictors of lifetime risk were examined using
discrete-time survival analysis with person-year as the unit of
analysis [37]. The predictors considered here were sex,
cohort, and a sex-by-cohort interaction. Cohort was deﬁned
by age at interview. We also examined a categorical version of
the cohort variable, which distinguished respondents who
were in the age ranges 18–29, 30–44, 45–59, and  60 y at
interview. The sex-by-cohort interaction was examined to
determine if the well-known gender difference in drug use
has become smaller in recent years in some or all countries
studied. Sociodemographic correlates of lifetime use at the
time of interview were examined using logistic regression
analysis [38]. Sociodemographic variables (e.g., family income,
relationship status) were coded as of the time of interview,
not as of the time of ﬁrst drug use, which means that the
associations examined might reﬂect inﬂuences of previous
drug use on sociodemographic characteristics. It is con-
sequently illegitimate to interpret the associations in tempo-
ral terms. Instead, the associations provide only cross-
sectional descriptive information. Standard errors of cumu-
lative incidence estimates, survival coefﬁcients, and logistic
regression coefﬁcients were estimated using the Taylor series
linearisation method [39] implemented in the SUDAAN
software system [40,41]. Survival coefﬁcients, logistic regres-
sion coefﬁcients, and their 95% conﬁdence intervals were
exponentiated and are reported in the form of odds ratios
(ORs) for ease of interpretation. Multivariate signiﬁcance
tests were made with Wald v
2 tests using design-based
coefﬁcient variance-covariance matrices. Signiﬁcance tests
were consistently evaluated at the 0.05 level with two-sided
tests.
Results
Cumulative Lifetime Incidence
Clear differences can be seen in the cumulative (lifetime)
incidence of drug use across countries (Table 2). Lifetime
alcohol use was reported by the vast majority of respondents
in the Americas, Europe, Japan, and New Zealand, while
considerably smaller proportions of respondents ever used
alcohol in the Middle East, Africa, and China. Lifetime
tobacco use was most common in the US (74%), Lebanon
(67%), Mexico (60%), and in some European countries
(Netherlands, 58%; Ukraine, 60%), with by far the lowest
proportions in the African countries (South Africa, 32%;
Nigeria, 17%). The proportions of respondents who ever used
cannabis were highest in the US (42%) and New Zealand
(42%), whereas lifetime cannabis use was virtually nonexis-
tent in the Asian countries (Table 2). The US was an outlier in
lifetime cocaine use, with 16% of respondents reporting that
they had tried cocaine at least once compared to 4.0%–4.3%
in Colombia, Mexico, Spain, and New Zealand, and extremely
low proportions in countries in the Middle East, Africa, and
Asia.
AOO Distributions
Figure 1 presents country-speciﬁc data on the AOO
distributions of drug use among those reporting use of each
drug type. As is clear from these graphs, there was remarkable
similarity in the AOO distributions for speciﬁc types of drugs
across countries. The median AOO was between 16–19 y for
alcohol for all countries except South Africa (20 y), and for
PLoS Medicine | www.plosmedicine.org July 2008 | Volume 5 | Issue 7 | e141 1056
Drug Use across the Globetobacco in all countries except Nigeria (21 y) and China (20 y).
The median AOO of illegal drug use was slightly older in all
countries. For cannabis, median AOO was between 18–19 y,
with the exception of Nigeria and Israel (both 22 y) and
Lebanon (21 y). Cocaine use typically began at a slightly older
age, with median AOO between 21–24 y for all countries
where sufﬁcient data were available to make an estimate.
Equally remarkable as the consistent median AOO across
countries is the age range of risk. Fully half the people who
had ever used alcohol began using in the 7-y age range
between 14–21 y. The interquartile range (IQR) (i.e., 25th–
75th percentiles) of AOO distributions were typically 15–21 y
for tobacco, 16–22 y for cannabis, and 19–28 y for cocaine.
Cross-National Differences in Lifetime Incidence in Recent
Cohorts
Table 3 characterises the drug use history of young adults
(22–29 y) in each country by age. Alcohol use by age 15 y was
far more common in European countries than in the Middle
East and Africa. By age 21 y, the vast majority of young adults
in European countries (76%–99%), Japan (92%), New
Zealand (94%), and the Americas (78%–93%) had begun
using alcohol; estimates were lower in the Middle East and
Africa (40%–63%). In the Netherlands, Belgium, France,
Germany, and New Zealand, .60% of young people had
started to drink by age 15 y. With three exceptions (South
Africa, Lebanon, and Nigeria), this threshold value of 60%
was crossed by age 21 y in all countries studied, with
especially large proportions starting to drink between ages
15 and 21 y in the Ukraine and Japan.
Data on age at ﬁrst tobacco smoking were available for
fewer countries; nonetheless, among those aged 22–29 y, an
estimated 46% of young adults in the Ukraine had started to
smoke by age 15 y, and 72% by age 21 y; similar estimates
were obtained in the US (44% and 72%, respectively). Nigeria
had the smallest estimated cumulative incidence proportion
for tobacco smoking by age 15 y (7%), and the following
intermediate estimates were observed: Israel (9%), South
Africa (11%), Colombia (12%), Peoples’ Republic of China
(15%), Lebanon (18%), Mexico (21%). The rank ordering of
countries with respect to use by age 21 y was almost identical
(Table 3).
Differences in illegal drug use were more marked among
young adults: by age 15 y, those in New Zealand (27%) and the
US (20%) had the highest levels of cannabis use, with almost
no use in Asia, Middle East, or Africa among this cohort. Few
young adults in the Netherlands had used cannabis by age 15
y (7%; Table 3). The majority of young adults in New Zealand
(62%) and the US (54%) had used by age 21 y, compared to
35% of those in the Netherlands.
Among this youngest cohort, cocaine use was extremely
rare in all countries at age 15 y. By age 21 y, young adults in
the US had by far the highest cumulative incidence of cocaine
use (16%; Table 3). In Colombia (the only cocaine-producing
country in this group) the estimate was 3%; and for the
Netherlands, 1%.
Sex and Cohort Differences in Lifetime Risk
Table 4 presents the results of discrete-time survival
analyses examining the association between cohort and ﬁrst
onset of use of each drug type. The model adjusts for age
differences in the cohorts by examining differential risk at
each year of life assuming linear associations between cohort
and risk. The associations are remarkably consistent across
countries and drug types, in that every one of the ORs is ,1.0,
indicating that risk at any given age is consistently higher in
more recent cohorts than in older cohorts. The ORs have
been normed to reﬂect relative-odds per 10 y of life. An OR
of 0.8, for example, indicates that the odds of ﬁrst use in any
given year of life is, on average, only 80% as high among
respondents who were age A at the time of interview
compared to respondents who were age A 10 y at interview.
These coefﬁcients assume, possibly incorrectly, that the
same relative-odds hold throughout the life course and
Table 2. Estimated Cumulative Incidence of Drug Use
Region Country Unweighted n Alcohol Tobacco Cannabis Cocaine
Percent SE Percent SE Percent SE Percent SE
Americas Colombia 4,426 94.3 0.5 48.1 1.2 10.8 0.6 4.0 0.4
Mexico 5,782 85.9 0.6 60.2 0.9 7.8 0.5 4.0 0.4
US 5,692 91.6 0.9 73.6 1.2 42.4 1.0 16.2 0.6
Europe Belgium 1,043 91.1 1.8 49.0 2.2 10.4 1.6 1.5 0.6
France 1,436 91.3 1.2 48.3 2.1 19.0 1.6 1.5 0.4
Germany 1,323 95.3 0.9 51.9 1.9 17.5 1.6 1.9 0.5
Italy 1,779 73.5 1.8 48.0 1.3 6.6 0.8 1.0 0.3
Netherlands 1094 93.3 1.4 58.0 1.9 19.8 1.3 1.9 0.2
Spain 2,121 86.4 1.1 53.1 1.8 15.9 1.3 4.1 0.7
Ukraine 1,719 97.0 0.6 60.6 1.8 6.4 1.0 0.1 0.0
Middle East and Africa Israel 4,859 58.3 0.8 47.9 0.7 11.5 0.5 0.9 0.1
Lebanon 1,031 53.3 3.0 67.4 2.6 4.6 0.9 0.7 0.3
Nigeria 2,143 57.4 1.6 16.8 1.1 2.7 0.5 0.1 0.1
South Africa 4,315 40.6 1.2 31.9 1.1 8.4 0.6 0.7 0.3
Asia Japan 887 89.1 1.6 48.6 2.0 1.5 0.4 0.3 0.3
People’s Republic of China 1,628 65.4 1.8 53.1 1.8 0.3 0.1 0.0 0.0
Oceania New Zealand 12,790 94.8 0.3 51.3 0.7 41.9 0.7 4.3 0.3
Data from the World Mental Health Surveys (n ¼ 54,068). Note: weighted cumulative incidence proportions. Standard error (SE) from Taylor series linearisation.
doi:10.1371/journal.pmed.0050141.t002
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Drug Use across the GlobeFigure 1. AOO of Drug Use among Those Reporting Any Use by Country
Note: Where lines are not presented for an individual country, either there was no assessment of the AOO of that drug, or fewer than 30 persons
reported having used the drug (see Tables 2 and 5).
doi:10.1371/journal.pmed.0050141.g001
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interview, but simplifying assumptions of these sorts are
needed to grasp such a wide range of associations all at once.
These assumptions are investigated next, but within the
context of these limitations, the data are clear in showing that
the dominant tendency in the data across countries, and
across drug types, is for risk to have increased over historical
time, deﬁned by the life courses of the respondents in these
surveys.
The easiest way to investigate the linearity assumption in
Table 4 is to examine AOO distributions across cohort, so as
to determine the extent to which between-cohort divergence
can be seen consistently over the life course. Such data are
presented in Figure 2, where the AOO distributions of drug
use are reconstructed based on retrospective AOO reports
using the actuarial method pooled across countries.
Focusing ﬁrst on the AOO curves for alcohol use, we can
see a clear nonlinear association across cohorts, with
respondents in the oldest cohort having a substantially lower
AOO curve than respondents in the more recent cohorts.
Although there is some evidence of higher risk of beginning
use in the late teens among the youngest compared to the
intermediate-aged cohorts, this difference is much less
dramatic than the evidence of lower risk in the oldest cohort.
It is also noteworthy that the intercohort variation, although
discernible prior to the late teens, is relatively small up to this
point in the life course, by which time roughly 60% of
respondents in each age cohort had started to drink. It was
largely in later-onset use rather than early-onset use that the
intercohort variation emerged most clearly, with initiation of
alcohol use continuing later on into young adulthood for
those in the younger cohorts.
For tobacco, the interval for risk of starting use was similar,
but the cumulative level was lower. There were no inter-
cohort differences until around age 21 y, by which age around
40% in each cohort had used. Of notable signiﬁcance, as for
alcohol, were the changes across cohorts after this age. The
highest overall level of use, reﬂecting continued initiation
into the mid-20s, was in the second oldest cohort; lower
cumulative levels (reﬂecting less initiation during the same
period of life) were observed among those in the two
youngest cohorts.
The interval of risk for starting cannabis use began in late
adolescence and continued far longer in life for all cohorts,
but very large intercohort differences were observed here,
with the oldest cohort dramatically lower than all others, and
the two youngest cohorts much higher than the second oldest
cohort. Clear and important age-speciﬁc differences were
also evident across cohorts: the two youngest cohorts were
very similar until the age of around 18 y in their cumulative
incidence of drug use—but initiation of cannabis use
continued to occur at a higher level following this age. A
similar and more marked difference between the second and
third cohorts was also evident, with initiation of cannabis use
highly unlikely to occur for the second oldest cohort after the
age of around 25 y. Clearly, then, two trends are evident: early
onset use is greater for the three youngest cohorts than for
the oldest, but much more marked is the fact that with each
successive cohort, there is a prolongation of the period of risk
for initiation of cannabis use far beyond adolescence.
The estimated cumulative incidence of cocaine use to age
Table 3. Estimated Cumulative Incidence of Drug Use by Age 15 and 21 y among 22–29 y Olds
Region Country Unweighted n Alcohol Tobacco Cannabis Cocaine
By 15 y By 21 y By 15 y By 21 y By 15 y By 21 y By 15 y By 21 y
Per-
cent
SE Per-
cent
SE Per-
cent
SE Per-
cent
SE Per-
cent
SE Per-
cent
SE Per-
cent
SE Per-
cent
SE
Americas Colombia 4,426 57.4 2.3 92.2 1.2 12.3 1.3 37.5 1.9 2.9 0.6 10.2 1.2 0.8 0.3 3.1 0.8
Mexico 5,782 29.0 1.9 77.5 1.2 21.4 1.4 52.5 1.6 2.2 0.5 8.0 1.1 0.6 0.3 4.1 0.7
US 5,692 50.1 2.5 93.1 1.3 43.6 2.4 71.6 2.8 20.2 1.8 54.0 2.8 2.5 0.8 16.3 1.6
Europe Belgium 1,043 67.0 8.3 88.5 6.1 —
a ——
a — 4.7 2.5 22.2 6.6 0.0 0.0 0.6 0.4
France 1,436 68.2 3.2 94.5 2.2 —
a ——
a — 15.3 4.3 44.1 5.3 0.0 0.0 1.9 1.3
Germany 1,323 82.1 3.2 97.8 1.1 —
a ——
a — 13.0 3.3 41.0 4.8 0.0 0.0 6.1 2.7
Italy 1,779 44.9 3.6 76.3 3.6 —
a ——
a — 3.3 1.1 13.7 2.5 0.0 0.0 0.9 0.6
Netherlands 1,094 59.6 7.7 89.7 6.4 —
a ——
a — 7.0 3.0 34.6 7.1 0.0 0.0 1.0 0.6
Spain 2,121 52.8 4.8 92.1 2.1 —
a ——
a — 8.5 2.6 27.7 4.4 0.1 0.1 5.3 1.8
Ukraine 1,719 39.3 3.9 98.5 1.1 46.0 4.9 72.1 3.9 1.3 0.7 12.3 2.6 —
b ——
b —
Middle East and
Africa
Israel 4,859 15.2 1.2 62.7 1.6 8.9 0.9 43.2 1.6 0.3 0.2 13.7 1.1 0.0 0.0 0.5 0.2
Lebanon 1,031 24.3 5.2 45.8 6.5 18.0 2.8 51.1 6.4 0.4 0.3 5.7 2.7 —
b ——
b —
Nigeria 2,143 31.4 3.2 52.5 3.1 6.9 1.7 10.1 1.7 0.2 0.2 1.9 0.9 —
b ——
b —
South Africa 4,315 9.4 1.4 39.5 2.0 11.0 1.6 31.0 1.6 1.6 0.5 11.0 1.4 —
b ——
b —
Asia Japan 887 30.4 6.7 91.9 5.8 —
a ——
a ——
b ——
b ——
b ——
b —
People’s Republic
of China
1,628 31.7 5.1 73.6 5.2 15.2 3.7 54.7 5.0 —
b ——
b ——
b ——
b —
Oceania New Zealand 12,790 74.1 1.5 94.1 0.9 —
a ——
a — 26.8 1.4 61.8 1.5 0.1 0.1 5.0 0.8
Data from the World Mental Health Surveys. Weighted data, Taylor series linearisation for variance estimation.
aNot asked in this country.
bFewer than 30 persons in the entire sample of this country used this drug, so estimates have not been produced.
SE, standard error.
doi:10.1371/journal.pmed.0050141.t003
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Drug Use across the Globe60 y was much lower than for the other drugs, making it
difﬁcult to derive a useful ‘‘interval of risk,’’ but the
intercohort differences appeared more linear—as can be
seen in Figure 2, the distance between curves for adjacent
cohorts was fairly consistent. Also clear is the fact that for
most cohorts, initiation of cocaine use continued into the
third decade of life, ﬂattening after age 30 y. It is unclear
whether such a trend would be observed when the youngest
cohort reached their thirties (given they have not yet passed
that age).
Are Women Catching Up to Men?
Table 5 presents country-speciﬁc estimates of the sex-age
interaction predicting incident drug use, again derived from
a discrete-time survival model. Sex was coded 1 for female
and 0 for male in this model. Evidence of women becoming
more similar to men in more recent cohorts would be
indicated by a sex-by-cohort interaction OR that was ,1.0:
this would mean that the relative-odds of use among women
compared to men were lower in older cohorts than younger
cohorts.
A negative interaction of exactly this sort was found fairly
consistently across countries. All 17 interactions for alcohol
use were ,1.0 (14 of them signiﬁcant at the 0.05 level). Seven
of nine interactions were ,1.0 in predicting tobacco use (ﬁve
of them signiﬁcantly so). The comparable counts were 13 of
15 interactions (ﬁve signiﬁcant) in predicting use of cannabis,
and six of 11 (two signiﬁcant) in predicting cocaine use. It is
noteworthy that the interactions are less consistent for illegal
drugs, although the pattern is in the same direction as for the
legal drugs.
Table 6 examines the possibility that given the sex-age
interactions presented in Table 5 above, that younger age
groups may no longer have sex differences in risk of incident
use (given that the differences were particularly marked
among older age groups). Two columns are shown for each
drug type: one for the entire sample, and one for those aged
18–29 y, each being the ratio of cumulative incidence
estimates according to sex (in any given year of life), derived
from discrete-time survival models. As can be seen, for the
overall sex association, there was an almost universal
association across countries and drug types, whereby women
were less likely than men in any given year of life to initiate
drug use of all kinds. Among those aged 18–29 y, however, less
consistent sex effects were found. In the European countries,
there was no effect of sex on the likelihood of initiating
alcohol use at any given age (with the exception of Italy and
Ukraine, where females were still slightly less likely). This
pattern was also found for cannabis and to a lesser extent
cocaine initiation in these countries. In Japan, China, and
New Zealand, no sex effect existed for alcohol initiation
among this youngest age group. In the remaining countries,
there remained a reduction of risk of incident drug use (of all
types) among females relative to males (Table 6).
Sociodemographic Correlates of Lifetime Use
Finally, Table 7 presents pooled analyses of associations
between drug use and six core demographic variables, with
covariate adjustments via multiple logistic regression terms
for each country (results from this pooled analysis are
consistent with associations observed in country-level analy-
ses; details of country-speciﬁc data are available upon
request). Some demographic variables were consistently
related to drug use of all kinds (Table 7). In particular, males
were more likely than females to have used all drug types and
younger adults were more likely than older adults to have
used all drug types. As noted above, these two associations
were consistent across drug types and countries. Income was
Table 4. Estimated Association between Cohort and Lifetime Risk of Each Drug, by Country
Region Country Alcohol Tobacco Cannabis Cocaine
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Americas Colombia 0.7* 0.7–0.7 1.0 0.9–1.0 0.7* 0.6–0.8 0.5* 0.4–0.6
Mexico 0.7* 0.7–0.7 0.8* 0.8–0.8 0.5* 0.4–0.6 0.2* 0.1–0.3
US 0.8* 0.8–0.8 0.9* 0.9–0.9 0.6* 0.6–0.6 0.5* 0.5–0.6
Europe Belgium 0.8* 0.8–0.9 —
a — 0.2* 0.1–0.3 0.1* 0.0–0.3
France 0.8* 0.8–0.9 —
a — 0.3* 0.2–0.4 0.4* 0.3–0.6
Germany 0.8* 0.8–0.9 —
a — 0.4* 0.3–0.5 0.2* 0.1–0.3
Italy 0.9* 0.8–0.9 —
a — 0.3* 0.3–0.4 0.6* 0.4–0.9
Netherlands 0.8* 0.8–0.9 —
a — 0.5* 0.4–0.5 0.5* 0.3–1.0
Spain 0.8* 0.8–0.8 —
a — 0.4* 0.3–0.4 0.3* 0.2–0.3
Ukraine 0.8* 0.8–0.8 0.7* 0.7–0.8 0.4* 0.3–0.5 —
b —
Middle East and Africa Israel 0.8* 0.7–0.8 0.9* 0.8–0.9 0.4* 0.3–0.4 0.4* 0.3–0.5
Lebanon 0.8* 0.8–0.9 0.8* 0.7–0.9 0.6* 0.4–0.9 —
b —
Nigeria 0.9* 0.8–0.9 1.2* 1.1–1.3 0.8 0.6–1.0 —
b —
South Africa 0.8* 0.7–0.8 0.9* 0.8–0.9 0.6* 0.5–0.7 —
b —
Asia Japan 0.7* 0.7–0.8 —
a ——
b ——
b —
People’s Republic of China 0.7* 0.6–0.8 0.8* 0.7–0.9 —
b ——
b —
Oceania New Zealand 0.8* 0.8–0.9 —
a — 0.5* 0.5–0.5 0.4* 0.4–0.5
Note: Results are based on a multivariable discrete-time survival model with person-year as the unit of analysis, in which predictors included cohort, sex, and person-year. Cohort in this
case is defined as a continuous variable.
aNot asked in this country.
bFewer than 30 persons in the entire sample of this country used this drug, so estimates have not been produced.
*, significant at p , 0.05, two-sided test.
CI, confidence interval.
doi:10.1371/journal.pmed.0050141.t004
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Drug Use across the Globepositively related to lifetime use of both legal and illegal
drugs. Marital status was also related to tobacco, cannabis,
and cocaine use, but not alcohol use, (with the never married
and previously married having higher odds of lifetime use
than the currently married). Although education was related
to drug use, the relationship was not consistent across drug
types. Education was positively related to lifetime alcohol use,
but negatively related to lifetime tobacco use, while education
was unrelated to lifetime illegal drug use.
Discussion
Globally, drug use is not distributed evenly. In general, the
US had among the highest levels of use of all drugs. Much
lower levels were observed in lower income countries in
Africa and the Middle East, and lower levels of use were
reported in the Asian locales covered.
These variations cannot be regarded as static: there was
greater drug involvement among younger than older adults in
all countries, suggesting that drug use has and may continue
to change over historical time. Interestingly, there was also
evidence to suggest that male-female differences in risk of
initiating drug use may be changing in more recent birth
cohorts. This change was a consistent ﬁnding across
countries, suggesting that a general shift may be occurring
with respect to the traditional sex differences so often
documented with drug use.
Consistent trends were also documented with respect to
the period of risk for initiation of drug use. In most countries,
the period of risk for initiation of use was heavily
concentrated in the period from the mid to late teenage
years; there was a slightly older and more extended period of
risk for illegal drugs compared to legal drugs. Analyses of
possible intercohort differences in risk of initiation suggested
not only that the levels of illegal drug use were higher, but
also that in more recent cohorts, the period of risk was
extending further into adulthood. This extension of the
period of risk has implications for drug use prevention
efforts, which often focus upon adolescents and do not
actively target young adults. Clearly, for illegal drugs, there
continues to be a window of risk of initiation of illegal drug
use that persists well beyond that of most commonly targeted
ages.
Legal and illegal use of drugs was most strongly associated
Figure 2. Age-Specific Cumulative Incidence of Drug Use by Birth Cohort
Pooled (weighted) data from the WMHSs (n ¼ 54,068).
doi:10.1371/journal.pmed.0050141.g002
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Drug Use across the Globewith age, sex, and income. Higher income was associated with
a greater likelihood of drug use for all drug types examined,
which is perhaps not surprising given that drug use requires
disposable income. Relationship status was linked to illegal
(but not legal) drug use: both cocaine and cannabis use were
more likely among persons who had never been married or
previously been married. These associations remained stat-
istically robust after adjustment for age, sex, and the other
variables considered here. These associations are consistent
with previous research in the developed countries, which has
linked illegal drug use with an individual’s marital status.
The use of drugs seems to be a feature of more afﬂuent
countries. The US, which has been driving much of the
world’s drug research and drug policy agenda, stands out with
higher levels of use of alcohol, cocaine, and cannabis, despite
punitive illegal drug policies, as well as (in many US states), a
higher minimum legal alcohol drinking age than many
comparable developed countries. The Netherlands, with a
less criminally punitive approach to cannabis use than the
US, has experienced lower levels of use, particularly among
younger adults. Clearly, by itself, a punitive policy towards
possession and use accounts for limited variation in nation-
level rates of illegal drug use.
Limitations
This study has limitations. We were limited to inclusion in
the study of the countries that had the resources and interest
in being involved in this exercise. Considerable effort was
expended to ensure that countries from every region world-
wide were represented in the consortium, but we did not
succeed in getting as much coverage as we would have liked;
for example, French-speaking West Africa is not represented
in the WMHS. This has meant that the current data do not
represent every world region sufﬁciently.
One limitation that certainly may have affected this study’s
estimates is the level of survey participation and non-
response, which varied across countries. This is a likely
source of underestimation of illegal drug involvement (and
perhaps alcohol and tobacco use), but not necessarily a source
of bias with respect to estimated associations with other
variables [42]. In the WMHS initiative, we compensated for
survey nonresponse via poststratiﬁcation adjustments, but
this approach is limited if nonresponse is associated with
drug use in other ways.
A considerable strength of the WMHS initiative is that the
population survey research approach generally has been held
constant. Each respondent has been sampled via advanced
population survey methods, has been presented with the same
type of survey introduction, and has completed a highly
structured and standardised ﬁeld survey interview assessment
using the same questions in each country, in accord with
standardised translations. One exception to this was France,
whose sampling frame only included households that had a
telephone, although interviewing itself was conducted face-
to-face.
Nonetheless, in a cross-national study such as this one,
there might be differential social stigma and legal practices in
each country that might affect self-reported drug use.
Attempts were made to ensure that truthful, honest answers
were provided by participants in these surveys in four major
ways. First, pilot testing in each country was carried out to
determine the best way to describe study purposes and
auspices in order to maximize willingness to respond honestly
and accurately. Second, in countries that do not have a
tradition of public opinion research, and where the notions
Table 5. Estimated Sex–Age Interaction Predicting Incident Use of Each Drug, by Country
Region Country Unweighted n Alcohol Tobacco Cannabis Cocaine
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Americas Colombia 4,426 0.7* 0.6–0.7 0.9 0.8–1.0 0.8 0.6–1.2 0.6 0.4–1.1
Mexico 5,782 0.6* 0.5–0.7 0.7* 0.7–0.8 0.7* 0.5–0.9 0.6* 0.4–0.8
US 5,692 0.9* 0.8–0.9 0.9* 0.9–0.9 1.0 0.9–1.0 0.9 0.9–1.0
Europe Belgium 1,043 0.8* 0.7–0.9 —
a — 0.9 0.7–1.4 2.2* 1.0–5.0
France 1,436 0.7* 0.6–0.8 —
a — 0.8 0.6–1.1 0.8 0.6–1.2
Germany 1,323 0.8* 0.7–0.9 —
a — 0.9 0.7–1.1 1.1 0.6–1.8
Italy 1,779 0.9* 0.8–1.0 —
a — 1.0 0.8–1.4 1.8 0.8–4.0
Netherlands 1,094 0.9 0.7–1.1 —
a — 0.8 0.6–1.2 1.0 0.5–1.8
Spain 2,121 0.7* 0.7–0.8 —
a — 0.8 0.6–1.0 0.9 0.7–1.1
Ukraine 1,719 0.7* 0.6–0.9 0.6* 0.5–0.6 0.4* 0.2–0.7 —
b —
Middle East and Africa Israel 4,859 0.9* 0.8–0.9 0.8* 0.8–0.9 0.8* 0.7–1.0 0.9 0.6–1.4
Lebanon 1,031 0.9 0.8–1.1 0.9 0.8–1.1 0.6 0.3–1.2 —
b —
Nigeria 2,143 0.9* 0.8–1.0 1.1 0.9–1.4 0.3* 0.1–0.5 —
b —
South Africa 4315 0.9 0.8–1.0 1.0 0.9–1.2 0.9 0.7–1.1 —
b —
Asia Japan 887 0.8* 0.7–0.9 —
a ——
b ——
b —
People’s Republic of China 1,628 0.8* 0.7–0.9 0.8* 0.7–0.9 —
b ——
b —
Oceania New Zealand 12,790 0.9* 0.9–0.9 —
a — 0.9* 0.8–0.9 1.0 0.8–1.1
Note: Results are based on multivariate discrete-time survival model with person-year as the unit of analysis, in which the predictors included sex, cohort, sex-by-cohort, and person-year.
Sex was coded 1 for female and 0 for male. Age cohort was divided by 10, such that a person aged 25 y would have a value of 2.5. In this way, a sex-by-cohort interaction with an OR ,1.0
means that the relative-odds of use among woman compared to men is increasing in more recent cohorts (i.e., in cohorts with the lowest age at interview).
aNot asked in this country.
bFewer than 30 persons in the entire sample of this country used this drug, so estimates have not been produced.
*, significant at p , 0.05, two-sided test.
CI, confidence interval.
doi:10.1371/journal.pmed.0050141.t005
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Drug Use across the Globeof anonymity and conﬁdentiality are unfamiliar, we con-
tacted community leaders in sample sites to explain the study,
obtain formal endorsement, and have the leaders announce
the study to community members and encourage participa-
tion. The announcements were most typically made by
religious leaders as part of their weekly sermons, although
there are other cases, such as the formal community leaders
in each neighbourhood in Beijing and Shanghai, where
secular community leaders, who were given presents by the
study organizers, made formal announcements and encour-
aged members of their neighbourhood to participate in the
survey. Third, interviewers were centrally trained in the use
of nondirective probing, a method designed to encourage
thoughtful honest responding. Finally, especially sensitive
questions were asked in a self-report format rather than an
interviewer-report format, although this could be done only
for respondents who could read. These methods were not
completely effective in removing cross-national differences in
willingness to report though, so it is important to recognise
the possible existence of remaining differences of this sort in
interpreting cross-national differences in results.
In future cross-national surveys, bioassays of drug use might
be included. In the interim, we must use population survey
data such as these to complement macro-level taxation
records that summarise only legal alcohol and tobacco use
across countries. These data are reasonable for developed
countries, but are likely to signiﬁcantly underestimate
consumption in some developing countries. The ﬁndings of
this study are consistent, however, with data collected in some
countries from other epidemiological studies, which have been
consistent with the ﬁndings here. The large cross-national
differences documented here are consistent with approxima-
tions of drug use levels given in the United Nations World
Drug Report [43] and with country-speciﬁc research—for
example, researchers have documented high levels of cannabis
use and early onset alcohol use in New Zealand [44], early
onset alcohol use in Europe, and cocaine use in the US [45].
It is important to note that we kept full age ranges because
we did not wish to truncate age in 90% of countries in order
to accommodate the few that had more restricted age ranges,
but we also wished to retain those few surveys in the total.
The presentation of estimates speciﬁc to the 18–29-y age
range is unaffected by these differences however, and the
same patterns of cross-country results was observed in that
instance. We also do not have an ‘‘urbanicity’’ variable in
most countries that could be considered comparable, so thus
far in the WMHS papers we have not studied urbanicity in
cross-national work.
Any cross-sectional survey research has limitations [46].
Some of the observed cohort differences might be traced to
higher mortality among individuals in the older cohorts who
began drug use at an early age. Nonetheless, we believe that
differential mortality is unlikely to explain the rather large
differences in cumulative incidence for illegal drug use across
age groups observed: in the case of cannabis, with substantial
age-related variations observed, there is no convincing
evidence of substantial premature mortality [47]. Conversely,
the evidence of tobacco-related premature mortality is
substantial, but tobacco use showed the least prominent
age-associated variation.
Table 6. Estimated Association between Sex and Incident of Use of Each Drug among the Total Sample, and among Young Adults (18–
29 y), by Country
Region Country Alcohol Tobacco Cannabis Cocaine
Total 18–29 y Total 18–29 y Total 18–29 y Total 18–29 y
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Americas Colombia 0.5* 0.5–0.6 0.6* 0.4–0.7 0.5* 0.4–0.5 0.4* 0.3–0.5 0.2* 0.1–0.3 0.3* 0.2–0.4 0.1* 0.1–0.2 0.2* 0.1–0.5
Mexico 0.4* 0.4–0.4 0.5* 0.4–0.6 0.4* 0.3–0.4 0.4* 0.3–0.5 0.1* 0.1–0.1 0.1* 0.1–0.2 0.1* 0.1–0.2 0.1* 0.1–0.2
US 0.7* 0.7–0.8 0.7* 0.6–0.9 0.7* 0.6–0.7 0.6* 0.5–0.7 0.6* 0.6–0.7 0.6* 0.5–0.7 0.5* 0.4–0.6 0.5* 0.4–0.7
Europe Belgium 0.7* 0.6–0.8 1.3 0.8–2.2 —
a ——
a — 0.7 0.5–1.0 0.6 0.3–1.1 0.6 0.2–1.5 0.1* 0.0–0.9
France 0.5* 0.5–0.6 0.7 0.4–1.1 —
a ——
a — 0.8 0.6–1.1 0.9 0.4–1.7 0.4 0.2–1.1 0.0* 0.0–0.4
Germany 0.7* 0.6–0.8 0.8 0.5–1.2 —
a ——
a — 0.6* 0.5–0.9 0.9 0.4–1.8 0.2* 0.1–0.5 0.2* 0.1–0.5
Italy 0.5* 0.4–0.6 0.6* 0.4–0.9 —
a ——
a — 0.3* 0.1–0.5 0.3* 0.1–0.6 0.3 0.1–1.1 0.3 0.0–4.7
Netherlands 0.7* 0.5–1.0 0.8 0.4–1.8 —
a ——
a — 0.7* 0.5–1.0 1.3 0.4–3.9 0.6 0.3–1.4 0.4 0.1–2.0
Spain 0.5* 0.5–0.6 0.7 0.5–1.2 —
a ——
a — 0.4* 0.3–0.5 0.6 0.3–1.1 0.3* 0.1–0.5 0.4 0.1–1.4
Ukraine 0.7* 0.6–0.8 0.7* 0.5–1.0 0.2* 0.2–0.2 0.3* 0.2–0.4 0.2* 0.1–0.4 0.4* 0.2–1.0 —
b ——
b —
Middle East
and Africa
Israel 0.5* 0.4–0.5 0.4* 0.4–0.5 0.4* 0.4–0.5 0.5* 0.4–0.7 0.5* 0.4–0.6 0.5* 0.4–0.7 0.2* 0.1–0.5 0.3* 0.1–0.9
Lebanon 0.4* 0.3–0.5 0.4* 0.2–0.7 0.6* 0.4–0.7 0.5* 0.2–0.9 0.2* 0.1–0.5 0.5 0.1–2.1 —
b ——
b —
Nigeria 0.5* 0.5–0.6 0.5* 0.4–0.7 0.0* 0.0–0.1 0.0* 0.0–0.1 0.0* 0.0–0.1 0.0* 0.0–0.4 —
b ——
b —
South Africa 0.3* 0.3–0.4 0.3* 0.2–0.4 0.2* 0.2–0.3 0.2* 0.1–0.2 0.2* 0.1–0.2 0.2* 0.1–0.3 —
b ——
b —
Asia Japan 0.6* 0.5–0.8 0.8 0.4–1.5 —
a ——
a ——
b ——
b ——
b ——
b —
People’s Republic
of China
0.5* 0.4–0.6 0.8 0.5–1.2 0.2* 0.1–0.2 0.3* 0.1–0.5 —
b ——
b ——
b ——
b —
Oceania New Zealand 0.7* 0.7–0.8 0.9 0.8–1.0 —
a ——
a — 0.7* 0.7–0.8 0.9 0.8–1.1 0.4* 0.3–0.6 0.4* 0.2–0.6
Results are based on multivariable discrete-time survival model with person-year as the unit of analysis, controlling for cohort
aNot asked in this country.
bFewer than 30 persons in the entire sample of this country used this drug, so estimates have not been produced.
*, significant at p , 0.05, two-sided test.
CI, confidence interval.
doi:10.1371/journal.pmed.0050141.t006
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Drug Use across the GlobeThis study found very strong cohort differences in illegal
drug use in particular. Although this may reﬂect actual
cohort differences in drug use, they may also reﬂect response
biases. Retrospective reporting of age of ﬁrst drug use may be
subject to error, given that respondents are being asked about
events that, for older persons, may have occurred decades
ago. Longitudinal studies of adolescents have found that
estimates of the age of ﬁrst use do tend to increase upon
repeat assessment (i.e. as people age), but the rank ordering
for different drugs remains the same [48–50].
It is unlikely that response or other biases completely
account for the strong trends observed here. In this study,
there were contrasting cohort trends across different drug
types, suggesting that a uniform bias or pattern of ‘‘forget-
ting’’ did not apply. Similar birth cohort trends in age of
initiation of illegal drug use have been observed in other
epidemiological studies in the US [51,52] and Australia [53],
some of which used data collected across time (rather than
relying solely on retrospective reports; e.g., see [51]).
In this paper, we have examined the cumulative incidence
(sometimes referred to as ‘‘lifetime prevalence’’) of use—this
includes both experimental and heavier use. We also focused
upon cumulative incident use rather than past year preva-
lence of use. Detailed examinations of prevalent (past year)
use, and of transitions to dependent use of these drugs, were
beyond the scope of the present paper, but are of obvious
interest and importance. These are the subjects of future
work currently being undertaken.
Conclusions
This study presents novel data on the epidemiology drug
use from representative, cross-national samples representing
all regions of the world. Clear differences in drug use existed
across the regions of the world, with the US estimated to have
among the highest levels of both legal and illegal drug use
among all countries surveyed. These differences may be
closing in more recent birth cohorts, with higher levels of
drug use seen among young adults across countries. Drug use
is related to income, but does not appear to be simply related
to drug policy, since countries with more stringent policies
towards illegal drug use did not have lower levels of such drug
use than countries with more liberal policies.
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Drug Use across the GlobeEditors’ Summary
Background. Understanding how much disability and death a particular
disease causes (known as the ‘‘burden of disease’’) is important.
Knowing the burden of a disease in a country contributes to the
development of healthier nations by directing strategies and policies
against the disease. Researchers’ understanding of the burden of
diseases across different countries was piecemeal until the 1990 launch
of a special World Health Organization (WHO) project, the Global Burden
of Disease Project. In 2002, on the basis of updated information from this
ongoing project, the WHO estimated that 91 million people were
affected by alcohol use disorders and 15 million by drug use disorders.
Why Was This Study Done? It is widely accepted that alcohol, tobacco,
and illegal drug use are linked with a considerable amount of illness,
disability, and death. However, there are few high-quality data
quantifying the amount across different countries, especially in less-
developed countries. The researchers therefore set out to collect basic
patterns of alcohol, tobacco, cannabis, and cocaine use in different
countries. They documented lifetime use of these substances in each
county, focusing on young adults. They also wanted to examine the age
of onset of use and whether the type of drugs used was affected by
one’s social and economic status.
What Did the Researchers Do and Find? Data on drug use were
available from 54,069 survey participants in 17 countries. The 17
countries were determined by the availability of collaborators and on
funding for the survey. Trained lay interviewers carried out face-to-face
interviews (except in France where the interviews were done over the
telephone) using a standardized, structured diagnostic interview for
psychiatric conditions. Participants were asked if they had ever used (a)
alcohol, (b) tobacco (cigarettes, cigars or pipes), (c) cannabis (marijuana,
hashish), or (d) cocaine. If they had used any of these drugs, they were
asked about the age they started using each type of drug. The age of
first tobacco smoking was not assessed in New Zealand, Japan, France,
Germany, Belgium, The Netherlands, Italy, or Spain. The interviewers also
recorded the participants’ sex, age, years of education, marital status,
employment, and household income.
The researchers found that in the Americas, Europe, Japan, and New
Zealand, alcohol had been used by the vast majority of survey
participants, compared to smaller proportions in the Middle East, Africa,
and China. The global distribution of drug use is unevenly distributed
with the US having the highest levels of both legal and illegal drug use
among all countries surveyed. There are differences in both legal and
illegal drug use among different socioeconomic groups. For example,
males were more likely than females to have used all drug types;
younger adults were more likely than older adults to have used all drugs
examined; and higher income was related to drug use of all kinds. Marital
status was found to be linked only to illegal drug use—the use of
cocaine and cannabis is more likely in people who have never been
married or were previously married. Drug use does not appear to be
related to drug policy, as countries with more stringent policies (e.g., the
US) did not have lower levels of illegal drug use than countries with more
liberal policies (e.g., The Netherlands).
What Do These Findings Mean? These findings present comprehensive
and useful data on the patterns of drug use from national samples
representing all regions of the world. The data will add to the
understanding of the global burden of disease and should be useful to
government and health organizations in developing policies to combat
these problems. The study does have its limitations—for example, it
surveyed only 17 of the world’s countries, within these countries there
were different rates of participation, and it is unclear whether people
accurately report their drug use when interviewed. Nevertheless, the
study did find clear differences in drug use across different regions of the
world, with the US having among the highest levels of legal and illegal
drug use of all the countries surveyed.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050141.
  Facts and figures on alcohol are available from the World Health
Organization, including information about the burden of disease
worldwide as a result of alcohol
  Information on the management of substance abuse is available from
WHO
  Information on the Global Burden of Disease Project is also available
from WHO
  Researchers from the University of New South Wales, Australia and the
University of Queensland co-chair, sponsors the Global Burden of
Disease Mental Disorders and Illicit Drug Use Expert Group, which
examines illicit drug use and disorders
  The UN World Drug Report is available from the UN Office on Drugs
and Crime
  The University of New South Wales also runs the Secretariat for the
Reference Group to the United Nations on HIV and Injecting Drug Use
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